Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436033 | 0.81 | SMN1; SMN2 (0.51) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL9523615 | 0.79 | EGFR (0.48) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18701121 | 0.78 | SMN1; SMN2 (0.46) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18083272 | 0.78 | IDO1 (0.52) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18701233 | 0.77 | HSD17B10 (0.45) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10978164 | 0.77 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2777859 | 0.77 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL18083271 | 0.76 | KDM4E (0.64) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| Iodide SCHEMBL2777739 | 0.76 | KDM4E (0.44) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8599938 | 0.73 | KDM4E (0.52) | KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054874-B1 | SUBSTITUTED AMINOPHENYL ISOXAZOLINE DERIVATIVES USEFUL AS ANTIMICROBIALS | UPJOHN CO (US) | 2002-08-28 | — | — | EP | claimed |
| US-7906541-B2 | Process to prepare new substituted 1H-benzo[d]imidazol-2(3H)-ones, new intermediates and their use as BACE 1 inhibitors | UNIVERSITE PAUL CEZANNE-AIX MARSEILLE III (FR) | 2011-03-15 | — | — | US | disclosed |
| WO-2010052670-A1 | PROCESS TO PREPARE NEW SUBSTITUTED 1H-BENZO [d] IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS | UNIVERSITE PAUL CEZANNE-AIX MARSEILLE III (FR) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120880-A1 | PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS | UNIVERSITE PAUL CEZANNE-AIX MARSEILLE III (FR) | 2010-05-13 | — | — | US | disclosed |
| EP-2184276-A1 | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors | UNIVERSITE PAUL CEZANNE AIX-MARSEILLE III (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-6642264-B1 | Thiazolo(3,2-a)benzoimidazole derivatives act specifically on metabotropic glutamate receptors and are used as medicaments. | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1167369-A1 | NOVEL THIAZOLOBENZIMIDAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120880-A1 | PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS | BACE1, BACE2, PSEN1 | KDM4E 3435/4885HSD17B10 1592/4885ALDH1A1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.